Pharmacy |
| ||
|
Combigan Generic Brimonidine Tartrate Timolol Maleate |
|
| ||
Home » Prescription Drugs 4 » Combigan Generic Brimonidine Tartrate Timolol Maleate CombiganÖ (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% is an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP; the IOP-lowering of CombiganÖ dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day. Buy Combigan Generic Brimonidine Tartrate Timolol Maleate and other Prescription Drugs 4 products online at Medstore. Buy Online at Medstore - Click Here!
About Combigan Generic Brimonidine Tartrate Timolol Maleate: Product Type: Prescription Drugs 4 Combigan ( Generic Brimonidine Tartrate & Timolol Maleate ) Combigan (Generic Brimonidine Tartrate & Timolol Maleate) Generic Brimonidine Tartrate & Timolol Maleate 0.2%/0.5% 30mL(6 x 5mL) 10mL(2 x 5mL) Generic Brimonidine Tartrate & Timolol Maleate Combigan
View more Prescription Drugs 4 Pharmacy: Dozens of patents for name-brand drugs are due to expire within the next 14 months, and generic drugs will replace some of the most popular and widely advertised drugs used today. For millions of people worldwide, this means switching from familiar brands like Lipitor to generic equivalents. How will this affect drug companies, and what will be the impact on people who depend on expensive prescription medication? Here, a brief guide: Which drugs are scheduled to go generic? Some real blockbusters. "In the next two years, six of the 10 top-selling drugs will lose their patents," says Chris Woolston in the Los Angeles Times. Lipitor, the world's best-selling drug, which is used to lower cholesterol, will be available as a generic in November of this year. Another best-seller, the blood thinner Plavix, will lose its patent in May 2012. Other well-known drugs with expiring patents include the arthritis treatment Enbrel, the anti-psychotic Zyprexa, as well as drugs for bipolar disorder, HIV, high cholesterol, and other conditions.
| ||
